Harvard Bioscience (HBIO) Announces Earnings Results

Share on StockTwits

Harvard Bioscience (NASDAQ:HBIO) issued its earnings results on Thursday. The medical instruments supplier reported $0.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.01, MarketWatch Earnings reports. The business had revenue of $28.23 million during the quarter, compared to analyst estimates of $28.50 million. Harvard Bioscience had a positive return on equity of 6.19% and a negative net margin of 2.87%.

NASDAQ HBIO traded down $0.82 on Friday, reaching $2.93. 983,932 shares of the stock traded hands, compared to its average volume of 122,418. The company has a quick ratio of 1.52, a current ratio of 2.69 and a debt-to-equity ratio of 0.71. The firm has a market cap of $110.37 million, a PE ratio of 19.53 and a beta of 1.34. Harvard Bioscience has a 12 month low of $2.75 and a 12 month high of $6.70.

In other Harvard Bioscience news, CEO Jeffrey Duchemin sold 6,332 shares of Harvard Bioscience stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $4.50, for a total transaction of $28,494.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.40% of the company’s stock.

A hedge fund recently raised its stake in Harvard Bioscience stock. Geode Capital Management LLC raised its position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 5.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 352,825 shares of the medical instruments supplier’s stock after purchasing an additional 18,372 shares during the period. Geode Capital Management LLC owned about 0.95% of Harvard Bioscience worth $1,121,000 as of its most recent filing with the Securities & Exchange Commission. 73.06% of the stock is currently owned by institutional investors.

HBIO has been the subject of a number of research analyst reports. Zacks Investment Research lowered Harvard Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. ValuEngine raised Harvard Bioscience from a “hold” rating to a “buy” rating in a research report on Saturday, February 23rd. Finally, Janney Montgomery Scott reaffirmed a “buy” rating on shares of Harvard Bioscience in a research report on Monday, February 18th.

COPYRIGHT VIOLATION WARNING: This story was originally published by Week Herald and is the property of of Week Herald. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://weekherald.com/2019/05/03/harvard-bioscience-hbio-announces-earnings-results.html.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.

Featured Article: Swap

Earnings History for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.